A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy
Clinical Trial Grant
Awarded By
Kardigan Inc.
Start Date
March 13, 2026
End Date
March 31, 2030
Awarded By
Kardigan Inc.
Start Date
March 13, 2026
End Date
March 31, 2030